Evidence map›Paper›PMID 39506618›Full record

ArticleAnnals of medicine2024

Katja Porvari, Kie Horioka, Helena Kaija, Lasse Pakanen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Amphiregulin in Fibrotic Diseases and Cancer.International journal of molecular sciences · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Katja PorvariResearch Unit of Biomedicine and Internal Medicine, Department of Forensic Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.ORCID 0000-0002-5692-243X
Kie HoriokaResearch Unit of Biomedicine and Internal Medicine, Department of Forensic Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.ORCID 0000-0002-9218-4905
Helena KaijaResearch Unit of Biomedicine and Internal Medicine, Department of Forensic Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.ORCID 0000-0003-1715-7023
Lasse PakanenResearch Unit of Biomedicine and Internal Medicine, Department of Forensic Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.ORCID 0000-0002-3494-7652

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmphiregulin (AREG) is a growth factor linked to cardioprotection and heart pathology during myocardial stress. Our aim was to investigate cardiac MATERIALS AND

methodsHeart RNA was isolated from hypothermic, cardiac and non-cardiac deaths. Relative

resultsThe

conclusionsSevere hypothermia activates cardiac

Indexed as

AmphiregulinHydrocortisoneHypothermiaMyocardiumRNA, MessengerAdultAgedAged, 80 and overBiomarkersEpinephrineFemaleHeart DiseasesHumansMaleMiddle AgedNorepinephrineAmphiregulinAREG protein, humanBiomarkersEpinephrineHydrocortisoneNorepinephrineRNA, MessengerAmphiregulincardiac stresscatecholaminescortisolhypothermia and cardiovascular deathsischaemiapostmortem hypothermia marker

Identifiers

PMID39506618
PMCPMC11544741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.